Sep 26, 2017
ST. LOUIS – BioGenerator, the investment arm of BioSTL, has won a $300,000 grant from the U.S. Department of Commerce to capitalize on its retooled investment strategy. That strategy is focused around quickly scaling companies to attract downstream investors, while also building new companies with a faster timeline to sales of commercial products or services.
To date, BioGenerator has invested $17.9 million into 71 companies. These investments attracted more than $530 million in additional capital from outside funders. BioGenerator’s ability to generate that 30x leverage places it among the leading early-stage investors in the country.